Loading
A phase 1/2 trial of CTX112 in hodgkin lymphoma and non-hodgkin lymphoma, run by CRISPR Therapeutics AG, now recruiting.
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies is a phase 1/2 interventional study registered as NCT05643742 by CRISPR Therapeutics AG, with 120 participants planned, started 2023-03-10 and due to reach its primary completion in 2030-01. Interventions recorded: CTX112. Conditions listed: B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/